Stage II-IIIB Non-small Cell Lung Carcinoma research hub

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

This study looks at a medicine called osimertinib for people with a certain type of lung cancer (NSCLC) that has been removed by surgery. It aims to see if taking the medicine for 5 years after surgery helps prevent the cancer from coming back.